3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Sarcoma
2
Other solid neoplasm
2
Gastrointestinal
2
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Breast Neoplasms
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
pembrolizumab
2
Cyclophosphamide
2
Cisplatin
2
sargramostim
1
regorafenib
1
fludarabine
1
entinostat
1
durvalumab
1
cemiplimab
1
avelumab
1
atezolizumab
1
abemaciclib
1
Surgical Procedures, Operative
1
Psychiatric Rehabilitation
1
Polymerase Chain Reaction
1
Platinum
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
Midazolam
1
Microarray Analysis
1
Megestrol Acetate
1
Levoleucovorin
1
Leucovorin
1
Letrozole
1
LY3023414
1
Interleukin-2
1
Interferon-gamma
1
Interferon-alpha
1
Immunoenzyme Techniques
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
regorafenib
×
Breast
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled